

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/774,176-Conf. #7186
				Filing Date	February 6, 2004
				First Named Inventor	Miles W. Carroll
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	1	of	1	Attorney Docket Number	31127/43656C

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	Bodey et al., "Failure of cancer vaccines: The significant limitations of this approach to immunotherapy," <i>Anticancer Res.</i> , 20:2665-2676, 2000.	
	C12	Boon, "Towards a genetic analysis of tumor rejection antigens," <i>Adv. Cancer Res.</i> , 58:177-210, 1992.	
	C13	DeGrujil et al., "Cancer vaccine strategies get bigger and better," <i>Nature Med.</i> , 5:1124-1125, 1999.	
	C14	Ezzell, "Cancer 'vaccines': An idea whose time has come?," <i>J. NIH Res.</i> , 7:46-49, 1995.	
	C15	Gaiger et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," <i>Blood</i> , 96:1480-1489, 2000.	
	C16	Oxford BioMedica announces FDA agreement on revisions for ongoing TroVax® phase III TRIST study. News 2008/OB/31, October 07, 2008.	
	C17	Oxford BioMedica reports data on association between immune response and patient survival from TroVax® trials in colorectal, renal and prostate cancer. News 2008/OB/33, October 24, 2008.	
	C18	Spitler "Cancer Vaccines: The interferon analogy," <i>Cancer Biother.</i> , 10:1-3, 1995.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.